Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

Carbohydrate antigen (CA) 19-9 identified by a murine monoclonal antibody against a colorectal carcinoma antigen is thought to be a sialylated Lewis (Le)a blood group antigen and occurs in high concentration in serum of patients with pancreatic carcinoma. This study was designed to identify the relationship between Lewis antigens and CA 19-9 in patients with pancreatic cancer. The following analyses were performed in 20 pancreatic cancer patients: Lea and Leb antigen phenotype in saliva (modified enzyme-linked immunosorbent assay) or on red cells (hemagglutination); CA 19-9 levels (radioimmunoassay) in serum; and CA 19-9 and Lea and Leb expression (immunoperoxidase assay) on tumor tissue. Lea-b- patients based on salivary phenotype failed to express CA 19-9 in tumor tissue and had normal or low levels of CA 19-9 (less than 37 units/ml) in serum (P = 0.0011, versus Lea+b- and Lea-b+ patients). Eighty-eight % of Lea+b- and Lea-b+ patients had elevated serum CA 19-9 levels (greater than 37 units/ml). All Lea+b- and Lea-b+ patients expressed both Lea and Leb antigens in tumor tissue. These results support the view that Lea-b- pancreatic cancer patients cannot manufacture CA 19-9. Surprisingly, Lea-positive patients express Leb antigen in tumor tissue; in this subgroup, Leb antigen may be a tumor-specific biomarker.

[1]  M. Brockhaus,et al.  A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. , 1982, The Journal of biological chemistry.

[2]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[3]  P. L. Mollison,et al.  Blood Groups in Man , 1962 .

[4]  H. Iishi,et al.  Values of CA 19‐9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor , 1985, Cancer.

[5]  M. Herlyn,et al.  Colorectal carcinoma antigens detected by hybridoma antibodies , 1979, Somatic cell genetics.

[6]  M. Brockhaus,et al.  Normal Salivary Mucin Contains the Gastrointestinal Cancer‐Associated Antigen Detected by Monoclonal Antibody 19–9 in the Serum Mucin of Patients 1 , 1985, Vox sanguinis.

[7]  L. Ferrell,et al.  Cancer-associated alterations of blood group antigen expression in human colorectal polyps. , 1986, Cancer research.

[8]  R. Tubbs,et al.  Measurement of a monoclonal‐antibody‐defined antigen (CA 19‐9) in the sera of patients with malignant and nonmalignant diseases comparison with carcinoembryonic antigen , 1985, Cancer.

[9]  M. Herlyn,et al.  Lewis blood group antigens defined by monoclonal anti-colon carcinoma antibodies. , 1984, Archives of biochemistry and biophysics.

[10]  M. Herlyn,et al.  Monoclonal antibody localization of Lewis antigens in fixed tissue. , 1984, Laboratory investigation; a journal of technical methods and pathology.

[11]  T. Klug,et al.  Initial clinical evaluation of an immunoradiometric assay for CA 19‐9 using the nci serum bank , 1984, International journal of cancer.

[12]  P. Pour,et al.  Presence of two distinct acinar cell populations in human pancreas based on their antigenicity , 1986, International journal of pancreatology : official journal of the International Association of Pancreatology.

[13]  M. Brockhaus,et al.  LEWIS BLOOD-TYPE MAY AFFECT THE INCIDENCE OF GASTROINTESTINAL CANCER , 1982, The Lancet.

[14]  M. Büchler,et al.  CA 19‐9 and pancreatic adenocarcinoma , 1986, Cancer.

[15]  A. Piccoli,et al.  CA 19‐9 and carcinoembryonic antigen in pancreatic cancer diagnosis , 1986, Cancer.

[16]  H. Sakahara,et al.  Serum CA 19‐9 concentrations and computed tomography findings in patients with pancreatic carcinoma , 1986, Cancer.

[17]  Y. Chung,et al.  A clinical evaluation of carbohydrate antigen 19‐9 and carcinoembryonic antigen in patients with pancreatic carcinoma , 1985, Journal of surgical oncology.

[18]  W. Schmiegel,et al.  Characterization of CA 19-9 bearing mucins as physiological exocrine pancreatic secretion products. , 1986, Cancer research.